K. S. Babu, Amirisetty Ravindranath Tagore, G. Reddy
May 31, 2010
Citations
0
Influential Citations
13
Citations
Journal
Arkivoc
Abstract
Olmesartan medoxomil 1 is the latest angiotensin receptor antagonist approved by the FDA for the treatment of hypertension. During the process development of olmesartan medoxomil, four related substances (impurities) were observed along with the final API. Those impurities were identified as olmesartan acid, 4-acetyl olmesartan, 5-acetyl olmesartan, and dehydro olmesartan. Present work describes the synthesis and characterization of all these four impurities.